Nanotechnology can provide a critical advantage in developing strategies for cancer management and treatment by helping to improve the safety and efficacy of novel therapeutic delivery vehicles.
This paper reports the fabrication of poly(lactic acid-co-glycolic acid)/siRNA nanoparticles coated with lipids for use as prostate cancer therapeutics made via a unique soft lithography particle molding process called Particle Replication In Nonwetting Templates (PRINT). The PRINT process enables high encapsulation efficiency of siRNA into neutral and monodisperse PLGA particles (32-46% encapsulation efficiency). Lipid-coated PLGA/siRNA PRINT particles were used to deliver therapeutic siRNA in vitro to knockdown genes relevant to prostate cancer.
Written by:
Hasan W, Chu K, Gullapalli A, Dunn SS, Enlow EM, Luft JC, Tian S, Napier ME, Pohlhaus PD, Rolland JP, Desimone JM. Are you the author?
Department of Chemistry, Department of Pharmacology, Department of Biochemistry and Biophysics, Carolina Center of Cancer Nanotechnology Excellence, Institute for Advanced Materials, Institute for Nanomedicine, and Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill, North Carolina 27599, United States.
Reference: Nano Lett. 2012 Jan 11;12(1):287-92. Epub 2011 Dec 21.
PubMed Abstract
PMID: 22165988
UroToday.com Investigational Urology Section
